Results from the phase 3 SCORED trial indicate that sotagliflozin protects kidney and heart health in individuals with type 2 diabetes and chronic kidney disease.
Traditional management of type 1 diabetes has primarily involved replacing the missing insulin with injections which, though effective, can be expensive and burdensome.
Investigators found that in patients with diabetes and cancer, sodium glucose cotransporter-2 inhibitors were associated with a higher risk of diabetic ketoacidosis and fracture...